Trial reportEuropean journal of nutrition2026
Phenolic-rich extruded BRS 305 sorghum-based beverage improves fecal and blood metabolites, oxidative balance and cardiometabolic markers in adults with excess body weight: a single-blind, randomized, placebo-controlled study.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of a phenolic-rich, extruded BRS305 sorghum-based beverage on fecal and blood metabolic, oxidative balance, and cardiometabolic parameters in adults with excess body weight.
methodsIn a single-blind, randomized, placebo-controlled study, 51 overweight adults of both sexes, were assigned to consume a sorghum beverage (SG, n = 25) or a control beverage (CG, n = 26), daily for 10 weeks, alongside a personalized hypocaloric diet (-500 kcal). The beverages phenolic profile was analyzed. Anthropometry, body composition, food intake, biochemicals, total plasma antioxidant capacity, oxidative stress, blood metabolite, fecal pH, short-chain fatty acids concentration, and Bristol stool scale were assessed at baseline and endpoint.
resultsThe sorghum beverage exhibited high diversity of phenolic compounds, including phenolic acids, flavonoids, and tannins, which reflected in higher plasma concentrations of trans-caffeic acid and naringenin in SG at the endpoint compared to the CG, along with an increase in total plasma antioxidant capacity. In the SG, superoxide dismutase and malondialdehyde decreased in intra-group, while catalase decreased at delta. In contrast, CG decreased nitric oxide levels and increased body fat percentage in intra-group. SG decreased insulin, triglycerides, HOMA-IR, and TyG index intra-group, maintaining body fat percentage; increased HDL-c and decreased Castelli I index at the endpoint; and decreased Castelli II index at delta. SG also decreased fecal pH and increased acetic acid content at endpoint and delta.
conclusionThese findings support the functional potential of extruded BRS305 sorghum-based beverage in improving fecal and blood metabolites, oxidative balance and cardiometabolic markers in adults with excess body weight.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.